Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 Ordinary Shares of JAZZ in an open-market transaction. The shares were sold at an average price of $235.12 per share. After this sale, he directly holds 372,682 Ordinary Shares of Jazz Pharmaceuticals.
The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the transaction timing was scheduled in advance and was not a discretionary trade by the reporting person.
Jazz Pharmaceuticals filing a Form 144 notice reporting proposed sales of 6,000 shares on multiple dates by Bruce Cozadd. The excerpt lists transactions dated 05/01/2026, 04/01/2026, and 03/03/2026 each showing 6,000 shares and associated amounts.
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported an open-market sale of 1,192 Ordinary Shares at $236.97 per share. After this transaction, she directly holds 52,626 shares.
The sale was executed automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026, indicating it was pre-scheduled rather than a discretionary trade based on short-term market conditions.
Jazz Pharmaceuticals executive Samantha Pearce reported an exercise-and-sale transaction in company stock. On May 28, 2026, the EVP, Chief Commercial Officer exercised non-qualified stock options to acquire 6,907 ordinary shares at an exercise price of $109.45 per share and sold 6,907 ordinary shares in an open-market transaction at $235.41 per share. Following these transactions, she directly owns 50,272 ordinary shares. The exercised options were granted under the company’s 2011 Equity Incentive Plan and had fully vested by March 2, 2024, and this specific option grant is now fully exercised.
Jazz Pharmaceuticals plc director Seamus Mulligan exercised a non-qualified stock option to acquire 3,415 Ordinary Shares at $138.08 per share. After this exercise, he holds 1,183,028 Ordinary Shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.
The option was originally granted on August 11, 2016 and had fully vested by August 1, 2017. Following this transaction, no shares remain under the exercised option, and there is no remaining derivative position reported in this filing.
Jazz Pharmaceuticals plc is soliciting proxies for its 2026 Annual General Meeting to be held on July 23, 2026 at its Dublin headquarters. Shareholders of record as of May 28, 2026 may vote on election of three Class III director nominees for three‑year terms, ratification of KPMG as auditor, a non‑binding say‑on‑pay, and two resolutions renewing board authority to allot and issue ordinary shares (including a special resolution to opt out of pre‑emption rights for issuances for cash up to 20% of issued ordinary share capital). Proxy voting deadlines and methods are described, and management will present Irish statutory financial statements for the year ended December 31, 2025.
Jazz Pharmaceuticals plc reported that director Anne O’Riordan, a Class III director whose term expires at the Company’s 2026 annual meeting of shareholders, has informed the board that she will not stand for re-election. The company notes this decision is not due to any dispute or disagreement with the company or its board on operations, policies, or practices. The board emphasized its commitment to ongoing board refreshment, board effectiveness, and orderly succession processes.
Jazz Pharmaceuticals director Rick E. Winningham exercised stock options and sold shares in the company. On May 22, 2026, he sold 2,741 Ordinary Shares in an open-market transaction at $241.57 per share, and exercised 3,415 Non-Qualified Stock Options at a $138.08 exercise price.
The options were originally granted in August 2016 and had fully vested by August 1, 2017. Following these transactions, Winningham directly holds 9,567 Ordinary Shares of Jazz Pharmaceuticals, indicating he retained a meaningful equity stake after the exercise-and-sale activity.